Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 18, 2009 - Issue 7
Submit an article Journal homepage
766
Views
80
CrossRef citations to date
0
Altmetric
Reviews

Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies

Matthew E Falagas Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece +30 694 611 0000; +30 210 683 9605; [email protected]; Henry Dunant Hospital, Department of Medicine, Athens, Greece; Tufts University School of Medicine, Department of Medicine, Boston, Massachusetts, USA
, MD MSc DSc,
Nikos Roussos Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece +30 694 611 0000; +30 210 683 9605; [email protected]
, MD,
Ioannis D Gkegkes Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece +30 694 611 0000; +30 210 683 9605; [email protected]
, MD,
Petros I Rafailidis Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece +30 694 611 0000; +30 210 683 9605; [email protected]; Henry Dunant Hospital, Department of Medicine, Athens, Greece
, MD MRCP UK MSc &
Drosos E Karageorgopoulos Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece +30 694 611 0000; +30 210 683 9605; [email protected]
, MD
Pages 921-944 | Published online: 24 Jun 2009

Bibliography

  • Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Med 2006;119:S11-9; discussion S62-70
  • Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006;368:874-85
  • Diep BA, Gill SR, Chang RF, et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 2006;367:731-9
  • Zirakzadeh A, Patel R. Vancomycin resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc 2006;81:529-36
  • Aguiar SI, Serrano I, Pinto FR, et al. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 2008;14:835-43
  • Richter SS, Heilmann KP, Dohrn CL, et al. Changing epidemiology of antimicrobial resistant Streptococcus pneumoniae in the United States, 2004-2005. Clin Infect Dis 2009;48:e23-33
  • Ratnaraja NV, Hawkey PM. Current challenges in treating MRSA: what are the options? Expert Rev Anti Infect Ther 2008;6:601-18
  • Korbila IP, Falagas ME. Investigational antimicrobial drugs for bloodstream infections. Curr Opin Investig Drugs 2008;9:871-8
  • Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-: a clinical super-challenge. N Engl J Med 2009;360:439-43
  • Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008;27:439-43
  • Goto S. Fosfomycin, antimicrobial activity in vitro and in vivo. Chemotherapy 1977;23(Suppl 1):63-74
  • Reeves DS. Fosfomycin trometamol. J Antimicrob Chemother 1994;34:853-8
  • Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46:1069-77
  • Performance standards for antimicrobial susceptibility testing: 18th informational supplement. Clinical and Laboratory Standards Institute, January 2008. Available from: http://www.clsi.org/
  • Graninger W, Leitha T, Havel M, Georgopoulos A. In vitro activity of fosfomycin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Infection 1984;12:293-5
  • Guenthner SH, Wenzel RP. In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1984;26:268-9
  • Alvarez S, Jones M, Berk SL. In vitro activity of fosfomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1985;28:689-90
  • Lau WY, Teoh-Chan CH, Fan ST, Lau KF. In vitro and in vivo study of fosfomycin in methicillin-resistant Staphylococcus aureus septicaemia. J Hyg (Lond) 1986;96:419-23
  • Utsui Y, Ohya S, Magaribuchi T, et al. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin-and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1986;30:917-22
  • Gatermann S, Schulz E, Marre R. The microbiological efficacy of the combination of fosfomycin and vancomycin against clinically relevant staphylococci. Infection 1989;17:35-7
  • Maple PA, Hamilton-Miller JM, Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet 1989;1:537-40
  • Van der Auwera P, Godard C, Denis C, et al. In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 1985. Antimicrob Agents Chemother 1990;34:2260-2
  • Wongwanich S, Tishyadhigama P, Paisomboon S, et al. Epidemiological analysis of methicillin resistant Staphylococcus aureus in Thailand. Southeast Asian J Trop Med Public Health 2000;31:72-6
  • Quentin C, Grobost F, Fischer I, et al. Antibiotic resistance of Staphylococcus aureus in urban experience: 6 month study in Aquitaine. Pathol Biol (Paris) 2001;49:33-40
  • Wootton M, Howe RA, Walsh TR, et al. In vitro activity of 21 antimicrobials against vancomycin-resistant Staphylococcus aureus (VRSA) and heteroVRSA (hVRSA). J Antimicrob Chemother 2002;50:760-1
  • Nakazawa H, Kikuchi Y, Honda T, et al. Enhancement of antimicrobial effects of various antibiotics against methicillin resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. J Infect Chemother 2003;9:304-9
  • Scholz H, Mehl M, Seifert H, Grabein B. In-vitro-aktivitat von fosfomycin und weiteren antibiotika gegenuber methicillin resistenten Staphylococcus-aureus-isolaten aus drei regionen deutschlands. Chemother J 2003;12:106-8
  • Vandenesch F, Naimi T, Enright MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9:978-84
  • Pistella E, Falcone M, Baiocchi P, et al. In vitro activity of fosfomycin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapy. Infez Med 2005;13:97-102
  • Witte W, Braulke C, Cuny C, et al. Emergence of methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin genes in central Europe. Eur J Clin Microbiol Infect Dis 2005;24:1-5
  • Mastouri M, Nour M, Ben Nejma M, et al. Antibiotics resistance of meticilline resistant Staphylococcus aureus: detection of the first glycopeptides low sensibility strains in Tunisia. Pathol Biol (Paris) 2006;54:33-6
  • Udo EE, Al-Sweih N, Noronha B. Characterisation of non-multiresistant methicillin-resistant Staphylococcus aureus (including EMRSA-15) in Kuwait hospitals. Clin Microbiol Infect 2006;12:262-9
  • Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis 2007;45:315-21
  • Higuchi W, Isobe H, Iwao Y, et al. Extensive multidrug resistance of coagulase-negative staphylococci in medical students. J Infect Chemother 2007;13:63-6
  • Kratzer C, Rabitsch W, Hirschl AM, et al. In vitro activity of daptomycin and tigecycline against coagulase-negative staphylococcus blood isolates from bone marrow transplant recipients. Eur J Haematol 2007;79:405-9
  • Takano T, Saito K, Teng LJ, Yamamoto T. Spread of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in Taipei, Taiwan in 2005, and comparison of its drug resistance with previous hospital-acquired MRSA. Microbiol Immunol 2007;51:627-32
  • Viallon A, Marjollet O, Berthelot P, et al. Risk factors associated with methicillin-resistant Staphylococcus aureus infection in patients admitted to the ED. Am J Emerg Med 2007;25:880-6
  • Molina A, Del Campo R, Maiz L, et al. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillin-resistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J Antimicrob Chemother 2008;62:961-7
  • Murbach V, Linger L, Barrand P, et al. Pneumococcal resistance to antibiotics in 1997/1998: results issued by the Alsace regional observatory. Med Mal Infect 2000;30:515-9
  • Chayakul P, Hortiwakul R. In vitro activities of penicillin g, cefotaxime, fosfomycin, fusidic acid and vancomycin against Streptococcus pneumoniae. J Infect Dis Antimicrob Agents 2004;21:41-6
  • Gravet A, Camdessoucens G, Murbach V, et al. Evolution of antibiotic resistance of Streptococcus pneumoniae: results of Alsace observatory in 2005. Pathol Biol (Paris) 2007;55:424-8
  • Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999;43:211-7
  • Fuchs PC, Barry AL, Brown SD. Fosfomycin tromethamine susceptibility of outpatient urine isolates of Escherichia coli and Enterococcus faecalis from ten North American medical centres by three methods. J Antimicrob Chemother 1999;43:137-40
  • Bonadio M, Meini M, Tagliaferri E, et al. Enterococcal glycopeptide resistance at an Italian teaching hospital. Br Soc Antimicrob Chemo 2000;129-31
  • Perri MB, Hershberger E, Ionescu M, et al. In vitro susceptibility of vancomycin resistant enterococci (VRE) to fosfomycin. Diagn Microbiol Infect Dis 2002;42:269-71
  • Shrestha NK, Chua JD, Tuohy MJ, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003;35:12-4
  • Cilli F, Pulluckcu H, Aydemir S. In vitro activity of fosfomycin tromethamine and linezolid against clinical vancomycin resistant Enterococcus faecium isolates. Clin Microbiol Infect 2007;13:167-8
  • Neves FP, Ribeiro RL, Duarte RS, et al. Emergence of the vanA genotype among Enterococcus gallinarum isolates colonising the intestinal tract of patients in a university hospital in Rio de Janeiro, Brazil. Int J Antimicrob Agents 2008;33:211-5
  • Kazmierczak A, Pechinot A, Tremeaux JC, et al. Bactericidal activity of cefotaxime and fosfomycin in cerebrospinal fluid during the treatment of rabbit meningitis experimentally induced by methicillin resistant Staphylococcus aureus. Infection 1985;13(Suppl 1):S76-80
  • Rodriguez A, Vicente MV, Olay T. Comparison of fosfomycin and vancomycin therapy for experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis. Eur J Clin Microbiol 1985;4:603-5
  • Rodriguez A, Vicente MV, Olay T. Single- and combination-antibiotic therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1987;31:1444-5
  • Thauvin C, Lemeland JF, Humbert G, Fillastre JP. Efficacy of pefloxacin fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1988;32:919-21
  • Chavanet P, Muggeo E, Waldner A, et al. Synergism between cefotaxime and fosfomycin in the therapy of methicillin and gentamicin resistant Staphylococcus aureus infection in rabbits. Eur J Clin Microbiol Infect Dis 1990;9:271-5
  • Morikawa K, Nonaka M, Yoshikawa Y, Torii I. Synergistic effect of fosfomycin and arbekacin on a methicillin-resistant Staphylococcus aureus-induced biofilm in a rat model. Int J Antimicrob Agents 2005;25:44-50
  • Chavanet P, Beloeil H, Pechinot A, et al. In vivo activity and pharmacodynamics of cefotaxime or ceftriaxone in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1995;39:1736-43
  • Chavanet P, Peyrard N, Pechinot A, et al. In vivo activity and pharmacodynamics of amoxicillin in combination with fosfomycin in fibrin clots infected with highly penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40:2062-66
  • Ribes S, Taberner F, Domenech A, et al. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006;57:931-6
  • Boulard G, Quentin C, Scontrini G, et al. Treatment of ventriculitis caused by Staphylococcus epidermidis on equipment with the combination of fosfomycin and an aminoglycoside. Course of ventricular levels of fosfomycin. Pathol Biol (Paris) 1983;31:525-7
  • Portier H, Tremeaux JC, Chavanet P, et al. A. Treatment of severe staphylococcal infections with cefotaxime and fosfomycin in combination. J Antimicrob Chemother 1984;14(Suppl B):277-84
  • Portier H, Armengaud M, Becq-Giraudon B, et al. Treatment with a cefotaxime fosfomycin combination of staphylococcal or enterobacterial meningitis in adults. Presse Med 1987;16:2161-6
  • Gouyon JB, Duez JM, Portier H, et al. Fosfomycin-cefotaxime combination in severe staphylococcal infections in newborn infants. Presse Med 1985;14:2135-8
  • Kono K, Takeda S, Tatara I, et al. Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections. Jpn J Antibiot 1994;47:798-803
  • Silbermann MH, Gyssens IC, Wielenga JJ, et al. A patient with acute leukemia and meningitis caused by Staphylococcus epidermidis treated with fosfomycin. Ned Tijdschr Geneeskd 1995;139:2498-501
  • Cassone M, Campanile F, Pantosti A, et al. Identification of a variant ‘Rome clone’ of methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin, responsible for an outbreak in an intensive care unit. Microb Drug Resist 2004;10:43-9
  • Apisarnthanarak A, Mundy LM. Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperazone/sulbactam and rifampin followed by fusidic acid and rifampin. Int J Infect Dis 2007;11:283-4
  • Yamasaki O, Morizane S, Akiyama H, et al. Tendon destruction induced by Panton-Valentine leukocidin-positive Staphylococcus aureus in a patient with Sezary syndrome. Br J Dermatol 2005;152:586-7
  • Salliot C, Zeller V, Puechal X, et al. Panton-Valentine leukocidin-producing Staphylococcus aureus infections: report of 4 French cases. Scand J Infect Dis 2006;38:192-5
  • Pouessel G, Ythier H, Carpentier O, et al. Childhood pustular psoriasis associated with Panton-Valentine leukocidin-producing Staphylococcus aureus. Ped Dermatol 2007;24:401-4
  • Olivier C, Cohen R, Beguι P, Floret D. Bacteriologic outcome of children with cefotaxime-or ceftriaxone-susceptible and-nonsusceptible streptococcus pneumoniae meningitis. Ped Infect Dis J 2000;19:1015-7
  • Patel SS, Balfour JA, Bryson HM. Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs 1997;53:637-56
  • Arca P, Reguera G, Hardisson C. Plasmid-encoded fosfomycin resistance in bacteria isolated from the urinary tract in a multicentre survey. J Antimicrob Chemother 1997;40:393-9
  • Etienne J, Gerbaud G, Fleurette J, Courvalin P. Characterization of staphylococcal plasmids hybridizing with the fosfomycin resistance gene fosB. FEMS Microbiol Lett 1991;68:119-22
  • Partridge SR, Hall RM. Gene cassettes potentially encoding fosfomycin resistance determinants. Antimicrob Agents Chemother 2005;49:860-1
  • Suarez JE, Mendoza MC. Plasmid-encoded fosfomycin resistance. Antimicrob Agents Chemother 1991;35:791-5
  • Forsgren A, Walder M. Antimicrobial activity of fosfomycin in vitro. J Antimicrob Chemother 1983;11:467-71
  • Perez Fernandez P, Herrera I, Martinez P, et al. Enhancement of the susceptibility of Staphylococcus aureus to phagocytosis after treatment with fosfomycin compared with other antimicrobial agents. Chemotherapy 1995;41:45-9
  • Trautmann M, Meincke C, Vogt K, et al. Intracellular bactericidal activity of fosfomycin against staphylococci: a comparison with other antibiotics. Infection 1992;20:350-4
  • Fujii R. Fosfomycin in the treatment of bacterial infections: summary of clinical trials in Japan. Chemotherapy 1977;23(Suppl 1):234-46
  • Hepping N, Simon A. Fosfomycin in paediatric cancer patients: a feasible alternative to glycopeptides? Int J Antimicrob Agents 2008;33:389
  • Thoumsin H, Aghayan M, Lambotte R. Single dose fosfomycin trometamol versus multiple dose nitrofurantoin in pregnant women with bacteriuria: preliminary results. Infection 1990;18(Suppl 2):S94-7
  • Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007;45:1350-2
  • Tenover FC, McDougal LK, Goering RV, et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 2006;44:108-18
  • Tristan A, Bes M, Meugnier H, et al. Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus, 2006. Emerg Infect Dis 2007;13:594-600
  • Mera RM, Miller LA, Daniels JJ, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: alexander project. Diagn Microbiol Infect Dis 2005;51:195-200
  • von Gottberg A, Klugman KP, Cohen C, et al. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study. Lancet 2008;371:1108-13
  • Bocchini CE, Hulten KG, Mason EO Jr, et al. Panton-Valentine leukocidin genes are associated with enhanced inflammatory response and local disease in acute hematogenous Staphylococcus aureus osteomyelitis in children. Pediatrics 2006;117:433-40
  • Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999;29:1128-32
  • Krause R, Patruta S, Daxbock F, et al. The effect of fosfomycin on neutrophil function. J Antimicrob Chemother 2001;47:141-6
  • Tullio V, Cuffini AM, Banche G, et al. Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing Escherichia coli. Int J Immunopathol Pharmacol 2008;21:153-60
  • Hamada M, Honda J, Yoshimuta T, et al. Fosfomycin inhibits neutrophil function via a protein kinase C-dependent signaling pathway. Int Immunopharmacol 2002;2:511-8
  • Rodriguez A, Gallego A, Olay T, Mata JM. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy 1977;23(Suppl 1):247-58
  • Hamilton-Miller JM. In vitro activity of fosfomycin against ‘problem’ Gram-positive cocci. Microbios 1992;71:95-103
  • Marchese A, Gualco L, Debbia EA, et al. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 2003;22(Suppl 2):53-9
  • Olsson-Liljequist B, Burman LG. Introducing fosfomycin for surgical prophylaxis: emergence of resistance in aerobic faecal gram-negative bacteria of in-patients, but not among strains causing infection after elective colorectal procedures. Scand J Infect Dis 1993;25:725-33
  • Greenwood D. Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis. Infection 1986;14:186-9
  • Georgopapadakou NH. Penicillin-binding proteins and bacterial resistance to beta-lactams. Antimicrob Agents Chemother 1993;37:2045-53
  • Kikuchi K, Totsuka K, Shimizu K, et al. Effects of combination of benzylpenicillin and fosfomycin on penicillin-resistant Streptococcus pneumoniae. Microb Drug Resist 1995;1:185-9
  • Grif K, Dierich MP, Pfaller K, et al. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001;48:209-17
  • Najioullah F, Pellon G, Freney J, et al. Fosfomycin enhances the expression of penicillin-binding protein 2 in methicillin-sensitive and methicillin-resistant Staphylococcus aureus strains. FEMS Microbiol Lett 1992;76:221-6
  • Holden MT, Feil EJ, Lindsay JA, et al. Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance. Proc Natl Acad Sci USA 2004;101:9786-91

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.